First Penny Picks Offers Analysis on the Following Micro-Cap Stocks and Launches VIP Early Alert Service
...continuedbiotech pharmaceutical peregrine
Related posts:
- First Penny Picks Offers Analysis on the Following Micro-Cap Stocks and Launches VIP Early Alert Service
- Elite Traders Group Offers Insights on the Following Micro-Cap Stocks and Launches VIP Early Alert Service
- Penny stocks from Micro stocks alert
- The Penny Stocks Guide Offers Expert Advice for Penny Stock Picks
- Micro Penny Stocks + Top Penny Stock Picks
OTC Stock Picks Newsletter Initiates Watch on Pharmaceutical Stock NovaBay …
OTC Stock Picks Newsletter Initiates Watch on Pharmaceutical Stock NovaBay …
The OTC Stock Picks newsletter is among the US market leaders in connecting small-cap and penny stocks to investors. With over two decades of market experience, the team prides itself on having the 'pulse' of the market. The company tracks over 100 …
Read more on Equities.com
To learn more about Pink Sheet Stocks Click Here
Find the Best Penny stocks to Invest in and and get all the latest Penny Stock News
Penny Stocks Trading Heavy Volume: TAGG, PWEI, SANP, ZERO, ONCS
(OTC:TAGG) is down 2.78% today at $ 0.1225. TAGG has traded 19.6 million shares so far today, more than double its daily average. TagLikeMe continues to release PRs at a near constant rate, which is normal for stocks undergoing a promotional campaign.
Read more on Active Investor
Top Traded Penny Stocks (AUGT, TAGG, CUAN, ONVO, MJNA)
We work hard to locate the next hottest penny stock. Forward · Print · Save. New York, NY — (SBWIRE) — 10/25/2012 — Augme Technologies, Inc. (OTC:AUGT) provides strategic services and mobile technology to consumer and healthcare brands.
Read more on SBWire (press release)
Related posts:
- OTC Stock Picks Newsletter Initiates Watch on Stock Navidea …
- OTC Stock Picks, a Leading Penny Stock Newsletter, Proudly Announces the …
- OTC Stock Picks, a Leading Penny Stock Newsletter, Proudly Announces the …
- OTC Stock Picks Newsletter Announces Alert On Awesome Penny Stock Pick …
- OTC Stock Picks Newsletter Announces Awesome Penny Stock Pick Mannkind …
Unigene to Target Partnering and Therapeutic Development Opportunities Following Victory Park Capital Debt Financing and Forbearance
...continuedstock pharmaceutical Accounting
Related posts:
- SaveDaily Enters Into Financing and Security Agreement for Up to $3,000,000 of Secured Convertible Debt Financing
- Standard Gold Announces a Forbearance Arrangement With Pure Path Capital Management Group LLC
- O2 Secure Wireless receives $50 Million Reserve Equity Financing from AGS Capital Group, LLC for the Development of its Building Projects Domestic and Abroad
- Response Biomedical Corporation Announces Debt Financing
- Victory Energy Announces $1.83 Million of New Capital Raised in The Month of January
Emisphere Technologies, Inc. Appoints Alan L. Rubino as President and Chief Executive Officer and Timothy G. Rothwell as Chairman of the Board of Directors; Announces New Corporate Strategy
...continuedbiotech pharmaceutical pharmaceuticals
Related posts:
- Emisphere Technologies Appoints Timothy McInerney and Jacob Plotsker to the Board of Directors
- Northcore Appoints Paul Godin as New Chairman of the Board of Directors
- Direct Insite Appoints John J. Murabito Chairman of the Board of Directors
- First Bank Appoints Patrick M. Ryan Vice Chairman of the Board of Directors
- BeesFree, Inc. Appoints Andrea Festuccia Non-Executive Chairman of the Board of Directors
Kim Thompson Posts Letter to the Shareholders on the Kraig Biocraft Laboratories Website
...continuedpharmaceuticals pharmaceutical biotechnology
Related posts:
- Kraig Biocraft Laboratories’ Monster Silkworms Pleased the Crowds at 2012 Techtextil North America
- Kraig Biocraft Laboratories to Host Conference Call to Discuss Commercialization and Laboratory Highlights
- MagneGas Posts New Demonstration Video to Website
- Nutra Pharma Letter to Shareholders
- Papa Bello Enterprises Kicks Off the Season with Letter to Shareholders
NanoViricides Appoints an Independent Board Director and Chairman of the Audit Committee
NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that Mr. Stanley Glick, CPA has been appointed as a Director of the Company and the Chairman of its Audit Committee. Mr. Stanley Glick, CPA, was appointed to the Board of Directors and the Audit Committee of the Company on June 22, 2012. Mr. Glick has over forty years of experience in his long career of providing auditing, accounting, tax, and management advisory services, to clients in various industries. Mr. Glick has been a memb...continuedNNVC pharmaceutical sec antiviral
Related posts:
- DATANG INTERNATIONAL POWER GENERATION COMPANY LD – Terms of Reference of the Audit Committee
- NanoViricides Announces Issuance of a Fundamental Patent in the USA
- NanoViricides, Inc. Announces That It Has Submitted a Pre-IND Meeting Request to the US FDA For Its Anti-Influenza Clinical Drug Candidate, FluCide(tm)
- Energy Telecom Appoints RBSM LLP as Its Independent Registered Public Auditing Firm
- Can-Cal Announces Final Closing of $0.06 Unit Financing and Appoints Ron Schinnour to the Board
IntelGenx Upgrades to OTCQX(R), the Highest Tier of the OTC Market, on June 14, 2012
Saint Laurent, Quebec--(Newsfile Corp. - June 14, 2012) - IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that its common stock will begin trading on the prestigious OTCQX® U.S. trading platform with effect from June 14, 2012. The OTCQX® is the highest tier of the OTC market and is exclusively for companies that meet the highest financial standards and undergo a qualitative review. IntelGenx’ trading symbol, IGXT, will remain the same. In addition, the...continuedIGX:CA IGXT sec pharmaceutical pharma
Related posts:
- IntelGenx Upgrades to OTCQX(R), the Highest Tier of the OTC Market, on June 14, 2012
- IntelGenx Named to the TSX Venture 50(R) Ranking
- IntelGenx Named to the TSX Venture 50(R) Ranking
- IntelGenx Named to the TSX Venture 50(R) Ranking
- IntelGenx Announces License Agreement for the Commercialization of CPI-300 in the United States
IntelGenx Upgrades to OTCQX(R), the Highest Tier of the OTC Market, on June 14, 2012
SAINT LAURENT, Quebec, June 14, 2012 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx") today announced that its common stock will begin trading on the prestigious OTCQX® U.S. trading platform with effect from June 14, 2012. The OTCQX® is the highest tier of the OTC market and is exclusively for companies that meet the highest financial standards and undergo a qualitative review. IntelGenx' trading symbol, IGXT, will remain the same. In addition, the Comp...continuedIGX:CA IGXT pharmaceuticals pharmaceutical shares
Related posts:
- IntelGenx Announces Development and Commercialization Agreement With Par Pharmaceutical, Inc.
- IntelGenx Named to the TSX Venture 50(R) Ranking
- IntelGenx Named to the TSX Venture 50(R) Ranking
- IntelGenx Named to the TSX Venture 50(R) Ranking
- IntelGenx Named to the TSX Venture 50(R) Ranking
Herborium Group Presented at The National Investment Banking Association, Inc. (NIBA) Conference in New York City, June 6th-8th, 2012
Herborium Receives Term Sheet From China Health Resource, Inc. FORT LEE, N.J., June 11, 2012 /PRNewswire/ -- Herborium Group, Inc. (OTC-PINK: HBRM) www.herborium.com is pleased to report that the presentation of the Company's unique Botanical Therapeutics® opportunity at the National Investment Banking Association, Inc. (NIBA) meeting in New York City, June 6th-8th, 2012 resulted in number of interests by NIBA professional members. To date NIBA member firms have successfully complete...continuedHBRM acupuncture pharmaceutical herb
Related posts:
- Herborium Group to Present to Investment Community at The National Investment Banking Association, Inc. (NIBA) Conference in New York City, June 6th-8th, 2012
- Amarantus BioSciences to Present at the National Investment Banking Association’s (NIBA)122nd Conference in New York City
- Glowpoint to Present at the National Investment Banking Association (NIBA) Investment Conference
- Clean Wind Energy Tower, Inc. Invited to Present at National Investment Banking Association (NIBA) Conference
- Amarantus BioSciences to Present at the National Investment Banking Association’s (NIBA) 120th Investment Conference
Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
Meeting Scheduled For June 18, 2012 WORCESTER, Mass. and TORONTO, June 7, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that an End-of-Phase II meeting has been scheduled with the United States Food and Drug Administration (FDA) in respect of the Phase II clinical trial of the AE37 breast cancer vaccine being undertaken by its wholly-owned subsidiary, Antigen Express, Inc. The meeting has been scheduled for June 18, 2012 with FDA regulatory management staf...continuedGNBT pharma pharmaceutical Healthcare
Related posts:
- Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
- Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
- Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
- Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
- Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television
Pharmos Corporation Announces Successful Completion Of Proof-of-concept Clinical Trial Of Levotofisopam For The Treatment Of Gout
RAPID AND SIGNIFICANT REDUCTION IN URIC ACID OBSERVED IN ALL SUBJECTS ISELIN, N.J., May 17, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a trial was conducted at the Duke Clinical Research Unit of Duke University and the principal investigator was John Sundy, MD, PhD, an expert and key opinion ...continuedPARS pharmaceutical pharma Healthcare
Related posts:
- Pharmos Provides Update on Ongoing Clinical Trial of Levotofisopam for the Treatment of Gout
- Pharmos Announces Dosing of First Patients in Clinical Trial of Levotofisopam for the Treatment of Gout
- ImmunoCellular Therapeutics Provides Update on Phase II Clinical Trial of ICT-107 for the Treatment of Glioblastoma
- Lightlake Therapeutics Inc. Announces Positive Preliminary Phase II Clinical Trial Results of Binge Eating Disorder Treatment
- Advaxis Announces Cancer Research UK Initiates Phase 1/2 Clinical Trial of ADXS-HPV for the Treatment of Head and Neck Cancer
Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
MALVERN, Pa. and MAHWAH, N.J., May 17, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) ("Auxilium") and FCB I LLC ("FCB") today announced that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent No. 8,178,518 covering, among other things, Testim® 1% testosterone gel, marketed by Auxilium under license from FCB. The newly issued patent, which claims certain pharmaceutical compositions comprising testosterone, is expected to expire in April 2023. Auxili...continuedAUXL XTLS pharmaceuticals pharmaceutical biotech
Related posts:
- Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering its Adva-27a Anti-Cancer Compound
- Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering its Adva-27a Anti-Cancer Compound
- Aradigm Selects Pulmaquin(tm) for Phase 3 Development and Announces Issuance of Its First U.S. Patent Covering Inhaled Ciprofloxacin Formulations
- NanoViricides Announces Issuance of a Fundamental Patent in the USA
- Patent Issued for Treatment of Diabetes
Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
Drs. Kathy D. Miller and Hope S. Rugo join SAB WORCESTER, Mass. and TORONTO, May 15, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT), in anticipation of the transition into pivotal Phase III trials, is pleased to announce today that the expertise of the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., has been expanded by the addition of two globally recognized experts in clinical trial research and immuno-therapeutic treatment...continuedGNBT GNTB biotechnology pharmaceutical Healthcare
Related posts:
- Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
- Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
- Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television
- Generex Announces Airing of Antigen Express Breast Cancer Vaccine Segment on Bloomberg Television
- Generex Subsidiary Antigen Express Announces Publication of Review Showcasing its Proprietary Therapeutic Vaccine Technology in the Journal Vaccine
NanoViricides Announces Issuance of a Fundamental Patent in the USA
NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that a fundamental patent, on which the nanoviricides® technology is based, is due to be issued in the USA on May 8, 2012. The issuance notification was received from the US Patents and Trademarks Office last week. The US Patent (No. 8,173,764) is granted for "Solubilization and Targeted Delivery of Drugs with Self-Assembling Amphiphilic Polymers." It will be issued on May 8, 2012. The patent term is expected to last through O...continuedNNVC pharmaceutical Accounting pharmaceuticals
Related posts:
- NanoViricides to Present at the 21st Annual NYBA Meeting in NYC on May 2nd
- NanoViricides, Inc. Announces That It Has Submitted a Pre-IND Meeting Request to the US FDA For Its Anti-Influenza Clinical Drug Candidate, FluCide(tm)
- NanoViricides Announces Successful Pre-IND Meeting with the US FDA
- NanoViricides Announces US FDA Has Confirmed Pre-IND Meeting Date
- NanoViricides Inc. Submits Pre-IND Briefing Document for its Anti-Influenza drug, FluCide(tm), to the US FDA
Kraig Biocraft Laboratories’ Monster Silkworms Pleased the Crowds at 2012 Techtextil North America
Company's Attendance Generates Additional Spider Silk Interest at North America's Only Dedicated Show for Technical Textiles and Nonwovens LANSING, Mich., May 1, 2012 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB.PK) (the "Company") announces that the Company exhibited its Monster Silk™ technology at the recently concluded Techtextil North America conference in Atlanta, Georgia. The Company's exhibit, which featured living transgenic silkworms, Monster Silk™ cocoons...continuedKBLB pharmaceuticals pharmaceutical Chemicals
Related posts:
- Kraig Biocraft Laboratories to Host Conference Call to Discuss Commercialization and Laboratory Highlights
- QinetiQ North America to Provide Marines In-Theatre Logistics and Inventory Support
- OncoSec to Present at 10th Annual BioPartnering North America
- New America Energy is Pleased to Provide the Following Updates to Shareholders
- Nissan North America Awarded 2012 Energy Star( Sustained Excellence Award
Viropro, Inc. Updates the Investment Community
(via Thenewswire.ca) IRVINE, California, April 19, 2012 -- VIROPRO (VPRO.PK). Management Updates on its Current Operations. Viropro is working diligently to increasing transparency and to bringing its financials fully up-to-date. The first statements consolidating Alpha Biologics Sdn. Bhd. require that Alpha's financials, which are prepared as per IFRS Standards, be translated to US GAAP. Furthermore, given the scope of the investment, Company is investigating whether a geographical segmentation ...continuedVPRO biotech pharmaceutical Healthcare
Related posts:
- Viropro, Inc. Updates the Investment Community
- Manas Retains Investor Relations Consultant to Broaden European Investment Community
- Manas Retains Investor Relations Consultant to broaden European investment community
- New America Energy is Pleased to Provide the Following Updates to Shareholders
- Glowpoint to Present at the National Investment Banking Association (NIBA) Investment Conference
Viropro, Inc. Updates the Investment Community
(via Thenewswire.ca) IRVINE, California, April 19, 2012 -- VIROPRO (VPRO.PK). Management Updates on its Current Operations. Viropro is working diligently to increasing transparency and to bringing its financials fully up-to-date. The first statements consolidating Alpha Biologics Sdn. Bhd. require that Alpha's financials, which are prepared as per IFRS Standards, be translated to US GAAP. Furthermore, given the scope of the investment, Company is investigating whether a geographical segmentation ...continuedVPRO biotechnology pharmaceutical Manufacturing
Related posts:
- Viropro, Inc. Updates the Investment Community
- Manas Retains Investor Relations Consultant to Broaden European Investment Community
- Manas Retains Investor Relations Consultant to broaden European investment community
- New America Energy is Pleased to Provide the Following Updates to Shareholders
- Glowpoint to Present at the National Investment Banking Association (NIBA) Investment Conference
Phase 2 Data on Provectus’s PV-10 to Be Presented at the HemOnc Today – Melanoma and Cutaneous Malignancies Conference on April 13, 2012
Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 study of PV-10 for metastatic melanoma will be presented at the HemOnc Today – Melanoma and Cutaneous Malignancies Conference on April 13, 2012. Professor Merrick Ross, M.D. of the MD Anderson Cancer Center in Houston, Texas, is scheduled to present at the HemOnc Today Conference in New York City. His presentation, e...continuedPVCT research pharmaceuticals pharmaceutical
Related posts:
- Data on Provectus’s PV-10 For Metastatic Melanoma Presented at the 2011 International Melanoma Congress
- Mechanism of Action Data On PV-10 Demonstrates Therapy Induces Immunologic Response
- Provectus Pharmaceuticals Will Present at the 2012 Maxim Group Growth Conference on March 26, 2012 in New York City
- Provectus Reports on Third End-of-Phase 2 Meeting with U.S. FDA to Define Pathway to Approval of PV-10 for Metastatic Melanoma
- Intralesional PV-10 Treatment Leads to the Induction of Anti-Tumor Immunity
Pharmos Provides Update on Ongoing Clinical Trial of Levotofisopam for the Treatment of Gout
RAPID AND SIGNIFICANT REDUCTION IN URIC ACID OBSERVED. ISELIN, N.J., April 5, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today provided an update on the ongoing clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a proof-of-concept trial is being conducted at the Duke Clinical Research Unit of Duke University and the principal investigator is John Sundy, MD, PhD an expert in the treatment of gout. The trial is d...continuedPARS pharmaceutical biotechnology biotech
Related posts:
- Pharmos Announces Dosing of First Patients in Clinical Trial of Levotofisopam for the Treatment of Gout
- ImmunoCellular Therapeutics Provides Update on Phase II Clinical Trial of ICT-107 for the Treatment of Glioblastoma
- Soligenix Announces Publication of Results of its Phase 2 Clinical Trial of orBec( in the Prevention of Acute GVHD
- OncoSec’s OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper
- PositiveID Corporation Announces Initiation of Clinical Trial of Its Easy Check Non-Invasive Breath Glucose Detection Device
Unigene’s Proprietary Oral Peptide Delivery Platform is Further Validated with Cara Therapeutics’ Successful Completion of its Phase 1 Study Using Unigene’s Oral Formulation of Novel Kappa Opioid Receptor Agonist, CR845
Robust 16% bioavailability and pharmacologic activity demonstrated with Unigene's oral formulation BOONTON, N.J., April 3, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) , a leader in the design, delivery, manufacture and development of peptide-based therapeutics today announced Cara Therapeutics, Inc. completed its successful, first-in-man Phase 1 clinical trial using Unigene's oral formulation of Cara's peptide-based, peripherally-restricted kappa opioid receptor ago...continuedUGNE unigene investment pharmaceutical
Related posts:
- Unigene’s Proprietary Peptelligence(tm) Platform Selected by Stealth Peptides for an Oral Phase 1 Clinical Study
- Unigene Announces Novartis’ Disclosure of First Interpretable Results from Phase 3 Trial of Calcitonin (SMC021) in the Treatment of Post-menopausal Osteoporosis
- Unigene Regains Exclusive Worldwide Rights of Oral PTH from GSK
- Unigene’s 2011 Year in Review – Key Elements in Place to Address Debt in 2012
- Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award
Intralesional PV-10 Treatment Leads to the Induction of Anti-Tumor Immunity
Moffitt Cancer Center Poster Presentation March 23 and 24, 2012 Results Detailed at the Society of Surgical Oncology Annual Meeting Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that nonclinical data on the immunologic mechanism of action of PV-10, presented at the 2012 Society of Surgical Oncology Annual Meeting, confirms that PV-10 chemoablation of melanoma lesions leads to a systemic response a...continuedPVCT pharmaceutical edgar investor
Related posts:
- Mechanism of Action Data On PV-10 Demonstrates Therapy Induces Immunologic Response
- Provectus Reports on Third End-of-Phase 2 Meeting with U.S. FDA to Define Pathway to Approval of PV-10 for Metastatic Melanoma
- Provectus Pharmaceuticals Will Present at the 2012 Maxim Group Growth Conference on March 26, 2012 in New York City
- Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
- Provectus Pharmaceuticals, Inc. and Its Subsidiaries Complete Unregistered Offering of Units to Facilitate Spin-off of Pure-ific Corporation
Mechanism of Action Data On PV-10 Demonstrates Therapy Induces Immunologic Response
- Results Detailed in Poster Presentation at the Society of Surgical Oncology Annual Meeting; Details of Poster Expected to Be Released Next Week - Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that nonclinical data on the immunologic mechanism of action of PV-10, presented at the Society of Surgical Oncology Annual Meeting, confirms that PV-10 chemoablation of melanoma lesions induces a systemic ...continuedPVCT pharmaceuticals Healthcare pharmaceutical
Related posts:
- Data on Provectus’s PV-10 For Metastatic Melanoma Presented at the 2011 International Melanoma Congress
- Provectus Reports on Third End-of-Phase 2 Meeting with U.S. FDA to Define Pathway to Approval of PV-10 for Metastatic Melanoma
- Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
- Provectus Pharmaceuticals, Inc. and Its Subsidiaries Complete Unregistered Offering of Units to Facilitate Spin-off of Pure-ific Corporation
- New Data on Vimpat( (lacosamide) C-V to Be Presented at the 65th Annual Meeting of the American Epilepsy Society
Quick-Med Technologies to Present Stay Fresh(R) Antimicrobial at AATCC International Conference
GAINESVILLE, Fla., March 16, 2012 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that Dr. Bernd Liesenfeld, principal scientist at Quick-Med, will deliver a podium presentation on Quick-Med's novel Stay Fresh Antimicrobial Technology at the 2012 International Conference, organized by the American Association of Textile Chemists and Colorists (AATCC). Dr. Lies...continuedQMDT biotech pharmaceutical Drugs
Related posts:
- USPTO Grants Quick-Med Technologies Sixth NIMBUS(R) Patent
- Quick-Med Expands NIMBUS(R) Technology Into Advanced Wound Care Dressings
- Ecosphere Technologies to Present at the 24th Annual ROTH Conference
- Location Based Technologies CEO Dave Morse to Present at the 4th Annual LD MICRO Growth Conference
- Structural Enhancement Technologies to Launch Select Cities Antimicrobial Restaurant Program
Emisphere Technologies, Inc. Announces Fourth Quarter and Year End 2011 Earnings Conference Call
Conference Call/Webcast to be Held Wednesday, March 21, 2012 at 10:00 AM ET CEDAR KNOLLS, N.J., March 15, 2012 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the fourth quarter and year ended December 31, 2011 on Wednesday, March 21, 2012 at 10:00 AM ET. A press release will be issued prior to market open. The live webcast of the conference call can be accessed...continuedEMIS strategy pharmaceutical pharmaceuticals
Related posts:
- NorCal Community Bancorp Announces Fourth Quarter Profit and Full Year Results
- Global Axcess Corp Announces Information for 2011 Fourth Quarter and Year End Financial Results Conference Call
- Global Telecom & Technology Announces Fourth Quarter and Year End Earnings Call
- AxoGen Announces Release Date of Year-End 2011 Results and Conference Call
- Cross Border Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2011 Financial Results
Generex Subsidiary Antigen Express Announces Publication of Review Showcasing its Proprietary Therapeutic Vaccine Technology in the Journal Vaccine
WORCESTER, Mass. and TORONTO, March 14, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that a review of the Antigen Express proprietary platform technology for generation of immunotherapeutic vaccines has been published in the peer-reviewed journal Vaccine . The Company is developing therapeutic vaccines for serious unmet medical needs, such as cancer. The article, entitled "CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class ...continuedGNBT generex Drugs pharmaceutical
Related posts:
- Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television
- Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
- Generex Announces Airing of Antigen Express Breast Cancer Vaccine Segment on Bloomberg Television
- Generex Announces Patent Award for its Core Vaccine Technologies in Japan
- Generex Provides Update on Bloomberg TV Breast Cancer Vaccine Segment